Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trialsJim M Smit, Henrik Endeman, Pierre François Dequin et al.|The Lancet Respiratory Medicine|2025Cited by 57
Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trialEsther Wittermans, Stefan M.T. Vestjens, Simone M.C. Spoorenberg et al.|European Respiratory Journal|2021Cited by 56
Neutrophil count, lymphocyte count and neutrophil-to-lymphocyte ratio in relation to response to adjunctive dexamethasone treatment in community-acquired pneumoniaEsther Wittermans, Willem Jan W. Bos, E.M.W. van de Garde et al.|European Journal of Internal Medicine|2021Cited by 22
Community-acquired pneumonia subgroups and differential response to corticosteroids: a secondary analysis of controlled studiesEsther Wittermans, Henrik Endeman, Philip van der Zee et al.|ERJ Open Research|2021Cited by 11
The extent of microbiological testing is associated with alteration of antibiotic therapy in adults with community-acquired pneumoniaEsther Wittermans, Bart J. M. Vlaminckx, Stefan M.T. Vestjens et al.|European Journal of Clinical Microbiology & Infectious Diseases|2019Cited by 6